Skip to main content

Advertisement

Table 3 Univariate and multivariate analysis for PFS

From: A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab

Covariate Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age (≥ 69 years) 0.7437 (0.4732–1.1688) 0.2015
Sex 1.313 (0.8109 -2.126) 0.268
Weight (≥ 69.5 kg) 1.1089 (0.6850–1.7950) 0.6756
Height (> 168 cm) 1.0502 (0.6274–1.7577) 0.8530
Liver metastasis 2.9391 (1.6952–5.0957) 0.0001 3.456 (2.002–5.965) < 0.0001
Lung metastasis 0.6133 (0.3818–0.9852) 0.0443
Lymph node metastasis 0.7610 (0.4697–1.2330) 0.2697
Only Lymph node metastasis 0.4324 (0.2567–0.7282) 0.0017
Brain metastasis 1.0419 (0.5639–1.9251) 0.8964
Malignant pleural effusion 1.0225 (0.4452–2.3485) 0.9583
Bone metastasis 1.5459 (0.9538–2.5057) 0.0786
Adrenal gland metastasis 1.2286 (0.6145–2.4563) 0.5623
N. of metastatic sites 1.1524 (0.8550–1.5533) 0.3542
ECOG PS 2.26 (1.602–3.187) < 0.0001 2.260 (1.580–3.233) < 0.0001
Line of treatment 1.0253 (0.7140–1.4724) 0.8928
Global     < 0.0001
  1. Italic values refer to statistically significant covariates (p value < 0.05) for PFS